AKT1 and breast cancer: Intra-tumoral activation of AKT has been correlated with resistance to multiple classes of inhibitors including EGFR inhibitors, estrogen receptor antagonists and aromatase antagonists in breast cancer and anti-hormone therapies in prostate cancer11–13.